presumed ocular histoplasmosis

pre·sumed oc·u·lar his·to·plas·mo·sis

subretinal neovascularization in the macular region associated with chorioretinal atrophy and pigment proliferation adjacent to the optic disc, and peripheral chorioretinal atrophy ("histo-spots").

pre·sumed oc·u·lar his·to·plas·mo·sis

(prē-zūmd' ok'yū-lăr his'tō-plaz-mō'sis)
Subretinal neovascularization in the macular region associated with chorioretinal atrophy and pigment proliferation adjacent to the optic disc, and peripheral chorioretinal atrophy ("histo-spots"); presumed secondary to infection by Histoplasma capsulatum.
References in periodicals archive ?
They may be large, solitary lesions, such as those seen following Toxoplasma infection, but sometimes they result in a "spotty" fundus appearance as seen in the presumed ocular histoplasmosis syndrome (POHS), birdshot chorioretinitis, multifocal choroiditis and pusctete inner choroidopathy (PIC).
Which of the following statements about Presumed Ocular Histoplasmosis Syndrome (POHS) is TRUE?
In addition, over 60 countries have approved Visudyne to treat other macular neovascular conditions such as minimally classic and occult with no classic AMD lesions, pathological myopia and presumed ocular histoplasmosis.
Nasdaq: QLTI; Toronto) has announced that the FDA has approved Visudyne(TM) (verteporfin for injection) therapy for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to pathologic myopia (severe near-sightedness) and presumed ocular histoplasmosis.
The current market drugs include Lucentis (ranibizumab), approved for CNV associated with wet age-related macular degeneration (AMD), Visudyne (verteporfin), approved for CNV associated with wet AMD, presumed ocular histoplasmosis and pathologic myopia, and Macugen (pegaptanib), approved for CNV associated with wet AMD.
Visudyne (verteporfin for injection) therapy is indicated for the treatment of patients with predominantly classic subfoveal choroidal neovascularization due to age-related macular degeneration, pathologic myopia or presumed ocular histoplasmosis.
In some countries Visudyne is also approved for presumed ocular histoplasmosis or other macular diseases.
Visudyne has received an additional approval for CNV due to presumed ocular histoplasmosis.
As part of the Canadian submission, Novartis Ophthalmics and QLT also filed for approval of Visudyne for presumed ocular histoplasmosis, a condition characterized by CNV resulting from a fungal infection of the retina.
Nasdaq: QLTI; Toronto) today announced that the United States Food and Drug Administration (FDA) has approved Visudyne(TM) (verteporfin for injection) therapy for the treatment of predominantly classic subfoveal choroidal neovascularization (CNV) due to pathologic myopia (severe near-sightedness) and presumed ocular histoplasmosis.
Dan Myers, president of Novartis Ophthalmics, North America said, "The fact that Visudyne therapy has demonstrated the ability to stabilise and in some cases improve vision in these pathologic myopia and presumed ocular histoplasmosis patients is another remarkable success story for this breakthrough therapy.